Human melanoma cells expressing the αvβ3 integrin are partially protected from necrotic cell death induced by dynamic matrix detachment

Cancer Letters

Volumn 290, Issue 2, 2010, Pages 174-181

  Tzukert, K ^a   Shimony, N ^a   Krasny, L ^a   Urieli Shoval, S ^a   Gorodetsky, R ^a   Avrahami, I ^b   Nettelbeck, D M ^c   Haviv, Y S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b AFEKA TEL AVIV ACADEMIC COLLEGE OF ENGINEERING   (Israel)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

v 3; Anchorage independence; Apoptosis; Dynamic matrix detachment; Melanoma; Necrosis

Indexed keywords

PROTEIN KINASE B; VITRONECTIN RECEPTOR;

ADHERENT CELL; ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MELANOMA CELL; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; VENOUS CIRCULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; HUMANS; INTEGRIN ALPHAVBETA3; MELANOMA; NECROSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 77649190047     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.09.007     Document Type: Article

References (34)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Shimony N., Avrahami I., Gorodetsky R., Elkin G., Tzukert K., Zangi L., Levdansky L., Krasny L., and Haviv Y.S. A 3-D rotary renal and mesenchymal stem cell culture model unveils cell death mechanisms induced by matrix deficiency and low shear stress. Nephrology Dialysis Transplantation 23 (2008) 2071-2080
3. Tzukert K., Gorodestky R., Avrahami I., Krasny L., Shimony N., Elkin G., Nettelbeck D., and Haviv Y. A novel dynamic matrix detachment model reveals a shift from apoptosis to necrosis in melanoma cells. Cancer Letters 272 2 (2008) 345-354
4. Rupp P.A., and Little C.D. Integrins in vascular development. Circulation Research 89 (2001) 566-572
5. Geiger B., Bershadsky A., Pankov R., and Yamada K.M. Transmembrane extracellular matrix-cytoskeleton crosstalk. Nature Reviews Molecular Cell Biology 2 (2001) 793-805
6. Meier F., Schittek B., Busch S., Garbe C., Smalley K., Satyamoorthy K., Li G., and Herlyn M. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Frontiers in Bioscience 10 (2005) 2986-3001
7. Hecker T.P., and Gladson C.L. Focal adhesion kinase in cancer. Frontiers in Bioscience 8 (2003) S705-S714
8. Gladson C.L., and Cheresh D.A. Glioblastoma expression of vitronectin and the alpha-v-beta-3 integrin - adhesion mechanism for transformed glial-cells. Journal of Clinical Investigation 88 (1991) 1924-1932
9. Nip J., Shibata H., JLoskutoff D., Cheresh D.A., and Brodt P. Human-melanoma cells derived from lymphatic metastases use integrin alpha-v-beta-3 to adhere to lymph-node vitronectin. Journal of Clinical Investigation 90 (1992) 1406-1413
10. Feldinghabermann B., Mueller B.M., Romerdahl C.A., and Cheresh D.A. Involvement of integrin alpha-v gene-expression in human-melanoma tumorigenicity. Journal of Clinical Investigation 89 (1992) 2018-2022
11. Albelda S.M., Mette S.A., Elder D.E., Stewart R.M., Damjanovich L., Herlyn M., and Buck C.A. Integrin distribution in malignant-melanoma - association of the beta-3-subunit with tumor progression. Cancer Research 50 (1990) 6664-6757
12. Montgomery A.M.P., Reisfeld R.A., and Cheresh D.A. Integrin-alpha-v-beta-3 rescues melanoma-cells from apoptosis in 3-dimensional dermal collagen. Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 8856-8860
13. Brassard D.L., Maxwell E., Malkowski M., Nagabhushan T.L., Kumar C.C., and Armstrong L. Integrin alpha-v-beta3-mediated activation of apoptosis. Experimental Cell Research 251 (1999) 33-45
14. Zhang Y., Lu H., Dazin P., and Kapila Y. Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis - fibronectin and integrin alpha(v)-mediate survival signals through focal adhesion kinase. Journal of Biological Chemistry 279 (2004) 48342-48349
15. Folkman J., and Moscona A. Role of cell-shape in growth-control. Nature 273 (1978) 345-349
16. Frisch S.M., and Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. Journal of Cell Biology 124 (1994) 619-662
17. Frisch S.M., Vuori K., Ruoslahti E., and ChanHui P.Y. Control of adhesion-dependent cell survival by focal adhesion kinase. Journal of Cell Biology 134 (1996) 793-799
18. Frisch S.M., and Ruoslahti E. Integrins and anoikis. Current Opinion in Cell Biology 9 (1997) 701-706
19. Meredith J.E., Fazeli B., and Schwartz M.A. The extracellular-matrix as a cell-survival factor. Molecular Biology of the Cell 4 (1993) 953-961
20. Lee Y., and Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. Journal of Biological Chemistry 274 (1999) 19792-19798
21. Englert R.P., and Shacter E. Distinct modes of cell death induced by different reactive oxygen species - amino acyl chloramines mediate hypochlorous acid-induced apoptosis. Journal of Biological Chemistry 277 (2002) 20518-20526
22. Schwartz M.A., McRoberts K., Coyner M., Andarawewa K.L., Frierson H.F., Sanders J.M., Swenson S., Markland F., Conaway M.R., and Theodorescu D. Integrin agonists as adjuvants in chemotherapy for melanoma. Clinical Cancer Research 14 (2008) 6193-6197
23. Lewis J.M., Truong T.N., and Schwartz M.A. Integrins regulate the apoptotic response to DNA damage through modulation of p53. Proceedings of the National Academy of Sciences of the United States of America 99 (2002) 3627-3632
24. Tzima E., del Pozo M.A., Shattil S.J., Chien S., and Schwartz M.A. Activation of integrins in endothelial cells by fluid shear stress mediates Rho-dependent cytoskeletal alignment. EMBO Journal 20 (2001) 4639-4647
25. Elicieri B., Stromblad S., and Cheresh D. Integrin alpha-v-beta-3-ligation requirement for a sustained MAP kinase signal essential for angiogenesis. FASEB Journal 11 (1997) A1290
26. Frisch S.M., and Screaton R.A. Anoikis mechanisms. Current Opinion in Cell Biology 13 (2001) 555-562
27. Eckert L.B., Repasky G.A., Ulku A.S., McFall A., Zhou H., Sartor C.I., and Der C.J. Involvement of RAS activation in human breast cancer cell signaling invasion and anoikis. Cancer Research 64 (2004) 4585-4592
28. Diaz-Montero C.M., Wygant J.N., and McIntyre B.W. PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires SRC activation. European Journal of Cancer 42 (2006) 1491-1500
29. Fukazawa H., Noguchi K., Murakami Y., and Uehara Y. Mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Molecular Cancer Therapeutics 1 (2002) 303-309
30. Collins N.L., Reginato M.J., Paulus J.K., Sgroi D.C., LaBaer J., and Brugge J.S. G(1)/S cell cycle arrest provides anoikis resistance through ERK-mediated BIM suppression molecular and cellular biology 25 (2005) 5282-5291
31. Kairouz-Wahbe R., Biliran H., Luo X., Khor I., Wankell M., Besch-Williford C., Pascual J., Oshima R., and Ruoslahti E. Anoikis effector Bit1 negatively regulates ERK activity. Proceedings of the National Academy of Sciences of the United States of America 105 (2008) 1528-1532
32. Khwaja A., RodriguezViciana P., Wennstrom S., Warne P.H., and Downward J. Matrix adhesion and RAS transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO Journal 16 (1997) 2783-2793
33. Gharbi S.I., Zvelebil M.J., Shuttleworth S.J., Hancox T., Saghir N., Timms J.F., and Waterfield M.D. Exploring the specificity of the PI3K family inhibitor LY294002. Biochemical Journal 404 (2007) 15-21
34. Petitclerc E., Stromblad S., von Schalscha T.L., Mitjans F., Piulats J., Montgomery A.M.P., Cheresh D.A., and Brooks P.C. Integrin alpha-v-beta-3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Research 59 (1999) 2724-2730